NCT03471260 2026-03-11
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
Clinical Trials
38 trialsNCT07463768 2026-03-11
MIVONU
French Innovative Leukemia Organisation
Phase 2 Not yet recruiting
NCT06707493 2026-03-10
Ivosidenib as Post-HSCT Maintenance for AML
Massachusetts General Hospital
Phase 2 Recruiting
NCT07392242 2026-03-06
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05756777 2026-03-05
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07260175 2026-02-23
adIVO
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT05876754 2026-02-19
ProvIDHe
Servier
Phase 3 Recruiting
NCT07006688 2026-02-18
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
Servier
Phase 1 Recruiting
NCT03343197 2026-02-17
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
Servier
Phase 1 Completed
NCT03155620 2026-02-10
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06127407 2026-02-06
CHONQUER
Servier
Phase 3 Recruiting
NCT04195555 2026-01-29
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05010772 2026-01-14
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07282262 2025-12-15
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT04493164 2025-11-21
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03173248 2025-11-10
AGILE
Servier
Phase 3 Active not recruiting
NCT04774393 2025-11-10
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06291987 2025-11-05
MPN
University of Chicago
Phase 1 Recruiting
NCT03564821 2025-11-04
IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
Phase 1 Completed
NCT04278781 2025-10-23
AG-120 in People With IDH1 Mutant Chondrosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05209074 2025-09-05
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT07131059 2025-08-20
MRD-positive AML Clinical Study
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT06717958 2025-07-02
PIVOT
Technische Universität Dresden
Phase 2 Recruiting
NCT02074839 2025-06-08
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Servier
Phase 1 Recruiting
NCT03503409 2025-05-18
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Groupe Francophone des Myelodysplasies
Phase 2 Active not recruiting
NCT05401097 2025-05-14
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT05615818 2025-04-23
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT02632708 2025-04-11
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Servier
Phase 1 Active not recruiting
NCT05907057 2025-04-11
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Servier
Phase 3 Recruiting
NCT04056910 2025-02-27
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
University of Pittsburgh
Phase 2 Completed
NCT04250051 2025-01-13
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
Northwestern University
Phase 1 Active not recruiting
NCT03839771 2024-10-02
HOVON150AML
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Active not recruiting
NCT02989857 2024-08-20
ClarIDHy
Servier
Phase 3 Completed
NCT04955938 2024-07-31
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
University of Chicago
Phase 1 Withdrawn
NCT04088188 2024-05-06
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Academic and Community Cancer Research United
Phase 1 Terminated
NCT04176393 2023-02-13
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
CStone Pharmaceuticals
Phase 1 Completed
NCT04655391 2022-06-09
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
City of Hope Medical Center
Phase 1 Withdrawn
NCT04044209 2022-01-20
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Yale University
Phase 2 Withdrawn